DepYmed Inc., is a New York based cancer and rare disease therapeutic development company. DepYmed is developing potent inhibitors of the enzyme PTP1B (protein tyrosine phosphatase 1B) with its current lead compound, MSI-1436C, in clinical development as a therapeutic candidate for HER2-positive breast cancer. In addition to PTP1B inhibitors, DepYmed has developed a portfolio of small molecules with copper chelating properties which can be applied as potential therapeutic agents for multiple diseases. DepYmed continues to develop the next generation of more potent PTP1B inhibitors / analogs as well as selective copper chelators which are currently in preclinical development in collaboration with Cold Spring Harbor Laboratory and continues to explore additional indications that may benefit from using PTP1B inhibitors and selective copper chelators as therapeutic agents.


Research & Development


Development Pipeline


Corporate News

Get In Touch

DepYmed, Inc.

3 Bioscience Park Drive
Farmingdale, NY 11735